Open AccessModular Antigen‐Specific T‐cell Biofactories for Calibrated In Vivo Synthesis of Engineered Proteins
Author(s) -
Repellin Claire E.,
Patel Puja,
Beviglia Lucia,
Javitz Harold,
Sambucetti Lidia,
Bhatnagar Parijat
Publication year - 2018
Publication title -
advanced biosystems
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.153
H-Index - 18
ISSN - 2366-7478
DOI - 10.1002/adbi.201800210
Subject(s) - reprogramming , in vivo , cell , computational biology , microbiology and biotechnology , modular design , biology , antigen , t cell , cancer research , immunology , immune system , computer science , biochemistry , genetics , operating system
An artificial cell‐signaling pathway is developed that capitalizes on the T‐cell's innate extravasation ability and transforms it into a vector ( T‐cell Biofactory ) for synthesizing calibrated amounts of engineered proteins in vivo. The modularity of this pathway enables reprogramming of the T‐cell Biofactory to target biomarkers on different disease cells, e.g. cancer, viral infections, autoimmune disorders. It can be expected that the T‐cell Biofactory leads to a “living drug” that extravasates to the disease sites, assesses the disease burden, synthesizes the calibrated amount of engineered therapeutic proteins upon stimulation by the diseased cells, and reduces targeting of normal cells.